Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
November 13 2019 - 9:21AM
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) today announced the
closing of its previously announced underwritten public offering of
common stock, including the exercise in full by the underwriters of
their option to purchase an additional 1,237,500 shares at the
public offering price of $31.00 per share. The exercise of the
option to purchase additional shares brought the total number of
shares of common stock sold by Agios to 9,487,500 shares and
increased the amount of gross proceeds, before underwriting
discounts and expenses, to approximately $294.1 million.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and
Cowen and Company, LLC acted as joint book-running managers for the
offering.
The shares were offered by Agios pursuant to an automatically
effective shelf registration statement that was previously filed
with the Securities and Exchange Commission (“SEC”). The offering
was made only by means of a prospectus and prospectus supplement
that form a part of the registration statement. The final
prospectus supplement relating to, and describing the terms of, the
offering has been filed with the SEC and is available on the SEC’s
web site at www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus relating to this offering can be obtained from J.P.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, New York 11717, telephone:
866-803-9204; Goldman Sachs & Co. LLC, Attn: Prospectus
Department, 200 West Street, New York, New York 10282, telephone:
866-471-2526, facsimile: 212-902-9316, e-mail:
prospectus-ny@ny.email.gs.com; or Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY, 11717, Attn: Prospectus Department, by email at
PostSaleManualRequests@broadridge.com, or by telephone at (833)
297-2926.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Agios Pharmaceuticals, Inc.
Agios is focused on discovering and developing novel
investigational medicines to treat cancer and rare genetic diseases
through scientific leadership in the field of cellular metabolism
and adjacent areas of biology. In addition to an active research
and discovery pipeline across both therapeutic areas, Agios has two
approved oncology precision medicines and multiple first-in-class
investigational therapies in clinical and/or preclinical
development. All Agios programs focus on genetically identified
patient populations, leveraging our knowledge of metabolism,
biology and genomics.
Investor & Media Contact: Holly Manning,
617-844-6630 Associate Director, Investor
RelationsHolly.Manning@agios.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Apr 2024 to May 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From May 2023 to May 2024